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Notable properties of the gut microbiota include its 
functionality and resilience1. A stable gut community 
protects the host against invading microorganisms and 
helps maintain homeostasis, including immune regula-
tion. Nonetheless, disruptions occur owing to dietary 
shifts, antibiotic use, age or infection, leading to a gut 
microbiota that can contribute to a range of inflam-
matory, pathogenic and metabolic conditions such as 
inflammatory bowel diseases, colorectal cancer, meta-
bolic syndrome and atopy2. Several strategies have been 
proposed to modulate the composition and/or func-
tion of the gut microbiota, including faecal microbiota 
transplants, the application of probiotics and other live 
microorganisms, and the use of non- digestible dietary 
substrates such as prebiotics3,4.
When the synbiotic concept was first described 
25 years ago, the notion that selectively fermentable 
non- digestible food ingredients (prebiotics) could be 
combined with probiotics was envisioned5. Thus, synbi-
otics were loosely defined as mixtures of “probiotics and 
prebiotics that beneficially affect the host”5. The term 
itself was formed from the Greek prefix ‘syn’, meaning 
‘together’ and the suffix ‘biotic’, meaning ‘pertaining to 
life’. Despite the availability of similarly worded defi-
nitions, confusion exists among stakeholders, includ-
ing scientists, about what constitutes a synbiotic6–9. 
A general misunderstanding might have been, in part, 
because the original definition itself — that is, “mixtures 
of probiotics and prebiotics that beneficially affect the 
host by improving the survival and implantation of live 
microbial dietary supplements in the gastrointestinal 
tract, by selectively stimulating the growth and/or by 
activating the metabolism of one or a limited number 
of health- promoting bacteria, thus improving host wel-
fare” — was too wordy and lacked precision5. In addi-
tion, the expansion of the entire ‘–biotics’ category, 
including terms such as postbiotic10 and pharmabiotic11, 
almost certainly further contributes to confusion. 
To provide clarity and guidance regarding appropriate 
use of the term ‘synbiotic’, in May 2019, the International 
Scientific Association for Probiotics and Prebiotics 
(ISAPP) convened an expert panel of academic scientists 
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to address the current status of synbiotics, including its 
definition. The outcomes of that meeting and subse-
quent discussions comprise this Consensus Statement. 
A summary of key conclusions is shown in Box 1. 
Herein, we consider applicable efficacy and mechanistic 
evidence on combination probiotic plus prebiotic prod-
ucts, we recommend the research needed to establish 
a ‘synbiotic’ formulation, discuss the safety considera-
tions, and reflect on implications for stakeholders of the 
synbiotic concept.
Methods
ISAPP is a non- profit collaboration of scientists dedi-
cated to advancing scientific excellence and providing 
objective, science- based information on probiotics and 
prebiotics. The organization’s activities are funded by 
companies involved in the sale of probiotics and prebiot-
ics, but ISAPP is guided by an international, all- volunteer 
academic board that functions independently. This 
ISAPP- organized panel was composed of experts in 
microbiology, nutrition and gastrointestinal physiology, 
including many who were involved in the latest updates 
of the probiotic12 and prebiotic13 definitions according to 
ISAPP. Panellists were charged with accomplishing the 
following goals: consider what a synbiotic is and pro-
vide a clear, concise and testable definition; suggest the 
appropriate experimental conditions necessary to estab-
lish synbiotic activity; describe the evidence required to 
demonstrate the health benefits and establish safety; and 
provide guidance for stakeholders, including research-
ers, industry, public health professionals and regulatory 
agencies.
Prior to the meeting, panellists developed a discus-
sion outline and target questions. During the meeting, 
panellists presented the perspectives and evidence 
regarding the core issues involved. Debate ensued until 
a consensus was achieved. After the meeting, individ-
ual panellists wrote sections of the summary, which 
were compiled by K.S.S., G.R.G., R.H. and M.E.S. into 
a draft report. This document was edited and agreed 
upon by all panel members. The authors would like to 
thank members of the ISAPP board of directors who 
did not directly participate in this consensus panel but 
who reviewed, criticized and approved this manuscript: 
D. Merenstein, H. Szajewska, M. Marco, E. Quigley, 
S. Lebeer and S. Salminen.
An updated definition
The panel updated the definition of a synbiotic to 
“a mixture comprising live microorganisms and sub-
strate(s) selectively utilized by host microorganisms 
that confers a health benefit on the host”. ‘Host’ micro-
organisms in this context include both autochthonous 
microorganisms (resident or colonizing the host) and 
allochthonous microorganisms (externally applied, 
such as probiotics), which, even if transiently present, 
do constitute a component of the host microbiota.
The panel considered defining synbiotics as simply 
a mixture of probiotics and prebiotics. Common to 
the definition of both probiotics and prebiotics is the 
requirement that each independently provides a health 
benefit and the dose of each must be adequate to inde-
pendently achieve those benefit(s). However, the panel 
recognized the possibility that a functional synbiotic 
could be formulated at doses below those at which the 
probiotic or prebiotic could independently exert health 
benefits. Alternatively, a particular microorganism 
might lack probiotic functions even at high dosages 
owing to competition or other ecological effects but, 
in the presence of a suitable substrate, could provide a 
health benefit. Likewise, a novel substrate, again even at 
high doses, might not by itself provide benefits but could 
do so when combined with a selected live microorgan-
ism(s) that it can enhance. Such formulations comprise 
a live microorganism and a substrate that depend on the 
presence of one another and function in concert. Simply 
put, the microbial component does not necessarily have 
to be a standalone probiotic and the non- digestible 
substrate does not necessarily have to be a standalone 
prebiotic, but, if together they provide a health benefit, 
then the mixture can be called a synbiotic. This pro-
posed definition of a synbiotic should encourage inno-
vation in formulations by not requiring that component 
parts meet the strict definitions of either a probiotic or 
a prebiotic.
However, the panel also recognized that a current 
common usage of the term synbiotic includes prod-
ucts that combine a probiotic and a prebiotic. Such a 
combination product might not have any evidence 
of co- dependent function but is instead designed for 
the components to work independently to promote an 
observed health benefit(s). The panel agreed that such 
a formulation could be considered a synbiotic, pro-
vided that components meet the respective probiotic12 
and prebiotic13 definitions (Fig. 1). Thus, the probi-
otic strain(s) is chosen based on the benefits that it 
provides to the host, while the prebiotic is designed to 
promote the growth and activities of beneficial mem-
bers of the indigenous microbiota and provide a health 
benefit14. Furthermore, a combination of probiotic plus 
prebiotic must be tested to confirm that a health bene-
fit is conferred by the combined formulation compared 
with a placebo. Otherwise, the product should not be 
labelled a synbiotic. Based on these qualifiers, the panel 
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retained the definition that a combination of a probiotic 
and a prebiotic be denoted as a complementary synbiotic 
(discussed later)14.
The other type of synbiotic previously envisioned 
is a synergistic synbiotic, which is a synbiotic in which 
the substrate is designed to be selectively utilized by the 
co- administered microorganisms. To be a synergistic 
synbiotic, the live microorganism is selected based on 
its ability to provide a health benefit and the substrate 
is chosen to primarily support the growth or activity of 
that selected microorganism14. Although the substrate 
might also enrich other beneficial members of the gas-
trointestinal microbiota, its main target is the ingested 
microorganism.
Designing and demonstrating the efficacy of a syn-
ergistic synbiotic is experimentally challenging. To our 
knowledge, nearly all synbiotics used in published clin-
ical trials or available commercially are of the comple-
mentary form15, irrespective of whether they have been 
deliberately designed or named as such. Approaches to 
designing complementary and synergistic synbiotics are 
shown in Fig. 2.
It is important to clarify that, although synbiotics can 
be formulated to provide synergistic activities, the ‘syn’ 
prefix in the word ‘synbiotic’ is not intended to imply 
synergy; it means ‘together’. Of note, the term ‘symbi-
otic’ is often misused in this context and is not the same 
as synbiotic. Symbiotic, as used in biology16, refers to 
an ecological relationship in which one organism (the 
symbiont) lives in a long- term relationship in a natu-
ral ecosystem with another organism (the host), that is, 
in symbiosis.
Characterization needed for synbiotics
A synbiotic should be characterized to the extent needed 
to ensure safety and a consistent performance. Live 
microbial component(s) of the synbiotic should have a 
publicly available genome sequence and annotation, be 
assessed for any genes of safety concern (for example, 
toxin production or transferrable antibiotic resistance), 
named using current taxonomic nomenclature and carry 
a traceable strain designation. The strain(s) should also 
be deposited into a recognized international culture 
collection that permits access by scientists to conduct 
research. In short, the safety, identity, purity and potency 
of the live microorganism should be clearly and accu-
rately described according to the best available meth-
ods that meet applicable regulatory standards for the 
product category.
The structure and purity of the substrate should be 
stated and characterized by appropriate chemical analy-
ses. This process includes testing for microbial and 
other contaminants as per regulatory standards for the 
country of sale. The level of purity required will depend 
on what is needed to ensure a consistent performance 
and safety of the product. The level of active substrate in 
commercial preparations of prebiotics available world-
wide ranges considerably, often from 35% to 99%17–19. 
The monosaccharides and disaccharides carried over 
from the production process that are present in pre-
biotic preparations are typically digested and absorbed 
by the host in the upper gastrointestinal tract after oral 
ingestion. A relevant issue is whether the material used 
in the formulation is sufficient to deliver a consistent 
dose of the active component and result in reproducible 
selective utilization by microorganisms and beneficial 
health effect(s) in the target host. This issue highlights 
that studies should communicate the content of the 
active ingredient being tested in addition to the quantity 
of the overall product. For example, a 6 g dosage of 50% 
pure galacto- oligosaccharides would provide 3 g of the 
active substrate and should be reported as such.
The active ingredients of a synbiotic must be suffi-
ciently stable. Ensuring stability of the live microbial 
component of a synbiotic can be challenging20. When 
live microorganisms are combined with a substrate(s) 
in a matrix (for example, liquid, dried or ointment), the 
burden is on manufacturers to ensure that the dosage 
of the live microorganism required to confer the stated 
health benefit is delivered throughout the shelf- life. 
Live microorganism viability is highly dependent on 
the matrix, storage temperature, pH and oxygen level 
of the product: for liquid products, the shelf- life might 
be as short as 1–2 weeks, for lyophilized or encapsu-
lated products, the shelf- life might be as long as 2 years. 
Packaging and storage conditions must control critical 
factors, such as water activity and temperature, through 
production to distribution and usage. Furthermore, 
a synbiotic must undergo assessment of safety for the 
intended use, as described later.
Current levels of evidence
Numerous randomized controlled trials (RCTs) in 
humans across a range of populations, from healthy 
individuals to those with acute and chronic diseases, 
Box 1 | Main conclusions of the consensus panel regarding synbiotics
•	The definition of synbiotic has been updated to “a mixture comprising live 
microorganisms and substrate(s) selectively utilized by host microorganisms that 
confers a health benefit on the host”.
•	Within this definition, ‘host’ microorganisms comprise both autochthonous (resident 
or colonizing the host) and allochthonous (externally applied, such as probiotics) 
microorganisms, either of which can be targets for the substrate contained in the 
synbiotic.
•	Two subsets of synbiotics were defined: complementary and synergistic. A ‘synergistic 
synbiotic’ is a synbiotic in which the substrate is designed to be selectively utilized by 
the co- administered microorganism(s). A ‘complementary synbiotic’ is a synbiotic 
composed of a probiotic combined with a prebiotic, which is designed to target 
autochthonous microorganisms. minimum criteria for the existing probiotic and 
prebiotic must be met for both components of a complementary synbiotic.
•	beneficial effect(s) of a synbiotic on health must be confirmed in the target host, 
which might include humans, companion animals, or agricultural species or a 
subpopulation (such as different age or developmental stage, health status, sex or 
living situation) thereof.
•	For a synergistic synbiotic, evidence of selective utilization of the substrate  
must be demonstrated in the same study establishing the health benefit. The aim  
is to demonstrate that the combined effect is better than the estimated effects  
of each component separately. This step is not required for a complementary 
synbiotic, as it contains a prebiotic for which selective utilization has already  
been established.
•	A synbiotic can be applied to intestinal or extra- intestinal microbial ecosystems and 
might be formulated into products fitting an array of regulatory categories (such as 
foods, non- foods, feeds, drugs or nutritional supplements).
•	Implied in the definition is that safety of the synbiotic for the intended use is established.
•	‘Symbiotic’ is not a synonym of synbiotic and is incorrect in this context.
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have been conducted to examine the health benefits of 
putative synbiotics. Many trials have been conducted in 
adults with metabolic diseases, including overweight and 
obesity21,22, type 2 diabetes mellitus23,24 and non- alcoholic 
fatty liver disease25,26. Other outcomes, such as irritable 
bowel syndrome27, surgical infections28,29, chronic kidney 
disease30,31 and atopic dermatitis32, have also been inves-
tigated. Consequently, many systematic reviews and 
meta- analyses of RCTs evaluating the effect of putative 
synbiotics on disease targets have been published22,23,32–35 
and this approach is an accepted means of evaluating the 
evidence for health benefits36–38. Examples are given in 
TaBle 1, which focuses on RCTs demonstrating benefits. 
Null trials have also been published across a variety of 
outcomes, including, for example, some studies aimed 
at the prevention of surgical infections39,40, treatment of 
obesity41, management of gestational diabetes mellitus42 
and eradication of Helicobacter pylori infection43,44. 
However, evidence of a health benefit is not in itself 
sufficient to call a formulation of live microorgan-
ism(s) plus selectively utilized substrate(s) a ‘synbiotic’. 
Concomitant evidence of selective utilization by either 
the endogenous microbiota (complementary synbiotic) 
or the co- administered live microorganism (synergistic 
synbiotic) must also be generated.
Across studies, species from the genera Lactobacillus, 
Bifidobacterium and Streptococcus are the most com-
monly used live microorganisms within the formulations 
tested. The substrate components are usually galacto- 
oligosaccharides, inulin or fructo- oligosaccharides 
but doses vary considerably, from as low as 100 mg to as 
much as 10–15 g per day. For example, in a double- blind 
RCT, twice daily consumption of a synbiotic composed 
of Lactobacillus acidophilus 10 (109 CFU), Lactobacillus 
rhamnosus HS111 (109 CFU), Lactobacillus casei 
10 (109 CFU), Bifidobacterium bifidum (109 CFU) and 
fructo- oligosaccharides (100 mg) 4 days before 
and 10 days after surgery for periampullary neoplasms 
resulted in a lower number of postoperative infec-
tions, a shorter duration of antibiotic therapy, fewer 
non- infectious complications, shorter length of hospi-
tal stay and reduced mortality than in patients receiving 
a placebo (sucrose)45. Although such low doses would 
not be expected to provide a prebiotic effect in comple-
mentary synbiotics, they could, in theory, be sufficient to 
stimulate a cognate microorganism in a synergistic syn-
biotic formulation. In one RCT46 of 225 adults with over-
weight and obesity, a combination of Bifidobacterium 
animalis subsp. lactis 420 and polydextrose (12 g per day) 
resulted in a relative reduction in body fat mass of 
4.5%, whereas the individual treatments had no effect. 
However, selective utilization was not established in this 
study. Thus, by itself, this study does not provide suffi-
cient evidence that the tested combination was either a 
complementary or a synergistic synbiotic.
In general, the appropriate dose, duration and com-
position of a synbiotic needed to confer a health benefit 
are likely to be specific to the context, including out-
come and baseline host target site microbiota47, as well 
as coexisting environmental factors such as medication, 
habitual diet and, perhaps, yet- to- be- identified host 
genetic factors.
Necessary evidence for synbiotics
A synbiotic must contain a live microorganism and 
a selectively utilized substrate. For complementary 
synbiotics, the respective components must fulfil the 
evidence and dose requirements for both a probiotic 
and prebiotic. Furthermore, the combination must 
be shown in an appropriately designed trial to confer 
a health benefit in the target host. A product contain-
ing a probiotic and a prebiotic that only has evidence 
for each component individually, and not as a combi-
nation product, should not be called a synbiotic. A key 
evidentiary requirement for a synergistic synbiotic is 
that there be at least one appropriately designed study 
of the synbiotic in the target host that demonstrates 
both selective utilization of the substrate and a health 
benefit (Box 2).
Generating this evidence requires appropriately 
designed, adequately powered experimental trials con-
ducted on the target host. These studies should follow 
standard human trial design and reporting guidelines48 
and consider best practices for diet–microbiota 
research49. The study should also meet the criteria out-
lined in CONSORT48 and should be registered, includ-
ing a description of all outcomes, prior to recruitment. 
These CONSORT criteria include guiding principles 
for microorganisms, microbiota- related compliance 
and outcome measures, relevant subgroups, and statis-
tical considerations for evaluating the microbiota as a 
mediator of clinical effects.
Synbiotic
Complementary synbiotic
Probiotic(s) + prebiotic(s) working 
to achieve one or more health benefits
• Probiotic: live microorganisms that, 
 when administered in adequate 
 amounts, confer a health benefit 
 on the host
• Prebiotic: a substrate that is selectively 
 utilized by host microorganisms 
 conferring a health benefit
Synergistic synbiotic
Substrate selected to specifically 
enhance the health benefit delivered 
by the co-administered live 
microorganism
• On its own, the live microorganism
 need not meet the criteria of 
 a probiotic
• On its own, the substrate need not 
 meet the criteria of a prebiotic
• Must be tested in the target host 
 demonstrating a health benefit 
• The study does not need to also 
 demonstrate selective utilization 
 as this has been previously 
 demonstrated by the prebiotic 
• Must be tested in the target host
• The study must demonstrate both 
 selective utilization and a health 
 benefit
Fig. 1 | Synbiotic categories. Synbiotics can be formulated using two approaches.  
A complementary synbiotic comprises a probiotic plus a prebiotic (more than one of 
each can be used), working independently to achieve one or more health benefits. 
Probiotic and prebiotic components of the complementary synbiotic must meet the 
minimum criteria, as stipulated previously12,13. A synergistic synbiotic is composed of a 
live microorganism and a selectively utilized substrate but neither needs to meet the 
minimum criteria stipulated previously for probiotics and prebiotics. Instead, these 
components are designed to work together, with the substrate being selectively utilized 
by the co- administered microorganism. The panel considered whether all synbiotics 
should be synergistic. However, the absence of such substances today speaks to the 
difficulty of achieving the required evidence. The panel judged that it was more important 
for the definition to be useful rather than hypothetical.
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Ideally, the health benefit of a synbiotic would 
be superadditive, that is, it would exceed the benefit 
observed for the sum of the individual components. 
However, owing to the difficulties in demonstrating 
different levels of health benefit in an efficacy trial, the 
panel did not insist upon this aspect. Instead, we advo-
cate requiring a measurable, confirmed health benefit of 
the synbiotic, which is conferred, at least in part, through 
selective utilization of the substrate(s) provided in the 
synbiotic. Although in vitro and animal models are used 
frequently to test the effects of probiotics, prebiotics and 
synbiotics50–53, it is our position that these have not been 
fully validated as predictive and that definitive tests of 
these interventions must be performed in the target 
host. Of course, model experiments can add mecha-
nistic insights, in particular in cases for which availa-
ble samples from studies in the target host have limited 
usefulness (for example, faeces, which are not reflective 
of upstream intestinal microbial or metabolic activities).
As noted, it is required that the health benefit of the 
synbiotic mixture be confirmed, even when established 
probiotic(s) and prebiotic(s) (that is, ones that meet cri-
teria stipulated in respective definitions and are used at 
efficacious doses) are used to formulate components of 
the synbiotic. This requirement would account for any 
potential antagonistic effect of the combination that 
might diminish the health benefits of each component 
independently. Although unlikely, such antagonism 
is theoretically possible, as shown in in vitro studies 
whereby some carbohydrate substrates increased the 
production of antimicrobial compounds by probiotics54. 
Depending on which microorganism is able to utilize 
the substrate, which antimicrobial factors are produced, 
and which taxa are neutralized or killed by them, such 
a scenario could lead to positive or negative outcomes. 
Therefore, in the absence of evidence that the combina-
tion product provides a health benefit, a product should 
simply be labelled as “contains probiotics and prebiot-
ics”. Sanders et al.55 provide a perspective on determining 
whether evidence from studies using one formulation 
(for example, a prebiotic or a probiotic alone) can be 
extrapolated to different formulations (for example, 
when combining a prebiotic and a probiotic).
Guiding principles for synbiotic research
Design. A randomized, double- blind, placebo- controlled 
trial is recommended for synbiotic research. The study 
should be registered with accepted protocol and results 
systems such as ClinicalTrials.gov. Study quality factors 
include, but are not limited to, appropriate blinding, 
randomization, the allocation concealment mechanism, 
reporting of inclusion and/or exclusion criteria and 
adverse events (AEs), completion of intention- to- treat 
analyses, and adequate statistical power. Crossover 
designs might be preferred to account for the individ-
ualized nature of the gut microbiota. The wash- out 
period length should be based on the primary outcome 
with consideration for secondary outcomes; a 2- week 
wash- out between conditions is generally adequate 
for gut microbiota outcomes, although longer times 
might be necessary for some populations (for example, 
the elderly or for those with constipation or functional 
bowel disorders). Parallel- arm designs might be required 
for long- term outcomes (such as weight loss or glycae-
mia). The number of study groups required depends on 
whether the researchers intend to demonstrate synergism 
(TaBle 2). Health outcomes and selective utilization of the 
substrate by host microbiota must be demonstrated in 
the same study. When experimental trials are not feasible or 
ethical, observational trials, including prospective longi-
tudinal studies, are useful; these studies must accurately 
capture synbiotic exposure and control for relevant 
confounders (such as diet or antibiotics).
Population or participants. When choosing the study 
population, many parameters need to be defined, includ-
ing the target host (including non- human species), tar-
get life stage (for example, pregnant women, infants, 
children, adults or elderly) and health status (for exam-
ple, healthy, at- risk, or with a diagnosed disease or con-
dition). Furthermore, microbiome- related factors, such 
as recent probiotic, prebiotic, synbiotic or antibiotic use, 
Complementary Synergistic
Substrate














Fig. 2 | Design and mechanisms of action of complementary and synergistic synbiotics. Two approaches to designing 
synbiotics are represented here. The complementary approach combines a prebiotic and a probiotic that work independently 
to elicit one or more health benefits. The prebiotic and probiotic must each meet applicable criteria (TaBle 3). The prebiotic 
functions by modulating the resident microbiota in a manner associated with an improved health outcome. The synergistic 
approach selects a substrate that is utilized by the co- administered live microorganism, enhancing its functionality. Synergistic 
synbiotics work together (not independently) to bring about the resulting health benefits.
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Table 1 | Human trials of orally administered combinations of live microorganisms and a substrate reporting health outcomes
Health 
outcome
Population studied Synbiotic used Refs





Adults, n = 54 GOS (12 g per day) Bifidobacterium breve strain Yakult (1×108/g), 
Lactobacillus casei strain Shirota (1×108/g) (3 g per day)
96
Adults, n = 79 FOS (dose not stated, three times 
per day)
Streptococcus faecalis T-110 (60 million), Clostridium 
butyricum TO- A (4 million), Bacillus mesentericus TO- A 
(2 million), Lactobacillus sporogenesa (100 million) (three 
times per day)
97
Adults, n = 80 Inulin, β- glucan, pectin and 
resistant starch (2.5 g of each, 
twice per day)
Pediococcus pentosaceus 5–33:3 (1010), Leuconostoc 
mesenteroides 77:1 (1010), Lactobacillus paracasei subsp. 
paracasei F19 (1010), Lactobacillus plantarum 2362 (1010) 
(twice per day)
98
Adults, n = 92 OFS (15 g, twice per day) Lactobacillus acidophilus La5, Lactobacillus bulgaricus, 
Bifidobacterium lactis BB-12, Streptococcus thermophilus 
(4×109 CFU) (three times per day)
99
Adults, n = 46 FOS (100 mg, twice per day) L. acidophilus 10 (1×109 CFU), Lactobacillus rhamnosus 
HS 111 (1×109 CFU), L. casei 10 (1×109 CFU), 
Bifidobacterium bifidum (1×109 CFU) (twice per day)
45
Adults, n = 61 GOS (10 g per day) B. breve strain Yakult (1×108/g), L. casei strain Shirota 






Adults, n = 52 FOS (250 mg per day) L. casei PXN 37 , L. rhamnosus PXN 54, S. thermophilus PXN 
66, B. breve PXN 25, L. acidophilus PXN 35, Bifidobacterium 
longum PXN 30, L. bulgaricus PXN 39 (2×108 CFU per day)
101
Adults, n = 66 FOS (dose not provided) B. longum (dose not provided) 102
Adults, n = 50 FOS (125 mg, twice per day) L. casei PXN 37 , L. rhamnosus PXN 54, S. thermophilus 
PXN 66, B. breve PXN 25, L. acidophilus PXN 35, B. longum 
PXN 30, L. bulgaricus PXN 39 (2×108 CFU, twice per day)
103
Adults, n = 75 Inulin HP (10 g per day) B. longum, L. acidophilus (2×107 CFU per day) 104
Prevention of 
sepsis in infants






Adults, n = 225 and n = 134 Litesse Ultra polydextrose  
(12 g per day)
Bifidobacterium animalis subsp. lactis 420 (1010 CFU 
per day)
46,106
Adults, n = 38 FOS (250 mg, twice per day) L. casei PXN 37 , L. rhamnosus PXN 54, S. thermophilus 
PXN 66, B. breve PXN 25, L. acidophilus PXN 35, B. longum 





Adults, n = 62 Inulin (0.36 g, three times per day) L. sporogenesa (9×107 CFU, three times per day) 108
Adults, n = 81 Inulin (0.07 g/1 g bread) (120 g per 
day as synbiotic bread)





Women with gestational 
diabetes, n = 70
Inulin (800 mg per day) L. acidophilus, L. casei, B. bifidum (2×109 CFU per day 
of each)
110
Adults with T2DM, n = 78 Inulin (0.07 g/1 g bread) (120 g per 
day as synbiotic bread)
L. sporogenesa (1×108 CFU/g, 120 g per day as synbiotic 
bread)
109
Adults with CHD and T2DM, 
n = 60
Inulin (800 mg per day) L. acidophilus, L. casei, B. bifidum (2×109 CFU/g of each 
per day)
111
Adults with T2DM, n = 62 Inulin (0.36 g, three times per day) L. sporogenesa (9×107 CFU, three times per day) 108
Treatment of 
inflammation
Elderly, n = 37 GOS (8 g per day) B. lactis Bi-07 (109 CFU per day) 112
Adults, n = 36 FOS (1.4 g per day) L. acidophilus La5, B. animalis ssp. lactis Bb-12, 
Lactobacillus delbrueckii ssp. bulgaricus, S. thermophilus, 
L. paracasei ssp. paracasei (2.4×109 CFU per day)
113
Adults with T1DM and T2DM 
on haemodialysis, n = 60






Adults, n = 85 FOS (100 mg, three times per day) Bacillus coagulans (15×107 spores, three times per day) 115




Adults, n = 76 FOS (250 mg per day) L. casei PXN 37 , L. rhamnosus PXN 54, S. thermophilus 
PXN 66, B. breve PXN 25, L. acidophilus PXN 35, B. longum 
PXN 30, L. bulgaricus PXN 39 (2×108 CFU per day)
117
Children and youth, n = 104 Inulin (900 mg per day) B. lactis B94 (5×109 CFU per day) 118
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microbiota- disrupting medications and diet can be con-
sidered as (in)eligibility criteria, depending on primary 
health and microbiota outcomes. A 2- week wash- in 
period is generally adequate for probiotics; however, 
certain populations might require longer wash- in peri-
ods (such as 4 weeks for those with slow transit time)56. 
The time since last antibiotic exposure will vary depend-
ing on a range of factors, including type of antibiotic, 
dose, duration and whether antibiotic use has occurred 
on multiple occasions in fairly short succession57,58. 
A general recommendation is difficult to make, although 
a common exclusion is individuals who have taken 
antibiotics 3 months prior to a study. However, at a 
minimum, 4 weeks since cessation of antibiotics is rec-
ommended. Non- antibiotic prescription medications 
should also be considered if they can influence bowel 
function and the microbiome59.
The population subgroups of interest should be 
specified. Clinical factors (such as sex or BMI), baseline 
microbiome features (such as presence of specific micro-
bial taxa) and other microbiome- relevant factors (such as 
dietary fibre intake, maternal secretor status for studies 
on human milk oligosaccharides or birth mode) might 
be relevant to analyse. For studies on the elderly, consider 
age- associated differences in transit time, gastric acidity 
and diet diversity. For mother–infant dyads, consider 
possible vertical transmission of microorganisms from 
mother to infant in breast milk, microorganisms and 
substrates naturally present in breast milk, and the 
unique characteristics of immature infant microbiome.
Intervention. The intervention should be fully described 
to enable replication of the study. This entails an ade-
quate description of substrate and live microorganism 
dosages, specification of the microbial strain, the struc-
ture and purity of the substrate, and the timing and route 
of administration of the intervention. Subject compli-
ance with an oral intervention can include measurement 
of the administered microorganisms in stool.
The duration of the intervention will be determined 
based on outcome; microbiota changes can be rapid 
but health outcomes will vary from days to weeks (such 
as constipation, stool frequency) to months (such as 
reduced fat mass, glycaemia). The background diet must 
be considered and, if possible, monitored as diet could 
provide a source of prebiotic substrates that are intrinsic 
and intact within certain foods (such as onions, wheat) 
as well as live microorganisms (such as fermented 
foods). Diet monitoring should include the use of val-
idated methods such as the National Cancer Institute 
Health 
outcome
Population studied Synbiotic used Refs





Adults, n = 60 Inulin (800 mg per day) L. acidophilus strain T16 (IBRC- M10785), L. casei strain 
T2 (IBRC- M10783), B. bifidum strain T1 (IBRC- M10771) 
(2×109 CFU/g of each per day)
119
Adults, n = 60 Inulin (800 mg per day) L. acidophilus strain T16 (IBRC- M10785), L. casei strain 
T2 (IBRC- M10783), B. bifidum strain T1 (IBRC- M10771) 





Adults, n = 30 Inulin (2.2 g), tapioca- resistant 
starch (1.3 g) (three times per day)
L. plantarum (5×109), L. casei subsp. rhamnosus (2×109), 
Lactobacillus gasseri (2×109), Bifidobacterium infantis 
(1×109), B. longum (1×109), L. acidophilus (1×109), 
Lactobacillus salivarius (1×109), L. sporogenesa (1×109),  
S. thermophilus (5×109) (3 times per day)
121
Adults, n = 66 FOS (500 mg capsule with 
undefined FOS dose, two capsules 
per day)
L. casei, L. acidophilus, L. bulgaricus, L. rhamnosus, B. breve, 
B. longum, S. thermophilus (500 mg capsule with undefined 
dose of microorganism, two capsules per day)
122
Adults, n = 37 Inulin, FOS, GOS (7.5 g per day for 
first 3 weeks then 15 g per day for 
second 3 weeks)
Nine different strains across Lactobacillus, Bifidobacterium 
and Streptococcus genera (45×109 CFU/day for first 





Pregnant women, n = 1,223 Newborn infants received the 
synbiotic: GOS (0.8 g, once per 
day)
Mothers received only the probiotic twice per day:  
L. rhamnosus GG (5×109 CFU), L. rhamnosus GG 
LC705 (5×109 CFU), B. breve Bb99 (2×108 CFU), 
Propionibacterium freudenreichii subsp. shermanii JS 





Infants 12–36 months of 
age, n = 90
FOS (50 mg, twice per day) L. acidophilus DDS-1, B. lactis UABLA-12 (5×109 CFU, 
twice per day)
125
Infants: 3 months to 6 years 
of age, n = 40
FOS (958 mg, twice per day) L. casei PXN 37 , L. rhamnosus PXN 54, S. thermophilus 
PXN 66, B. breve PXN 25, L. acidophilus PXN 35, B. infantis 
PXN 27 , L. bulgaricus PXN 39 (1×109 CFU, twice per day)
126
Children: 2–14 years of age, 
n = 60
FOS (475 mg, twice per day) L. salivarius PM- A0006 (2×109 CFU, twice per day) 127
The selected studies contained in this table represent blinded, randomized, controlled trials that showed a health benefit of the combination product. Studies 
listed did not necessarily test both the health benefit and selective utilization by the microbiota, so we have avoided the use of the term ‘synbiotic’ in this table. Null 
trials and studies using the inappropriate term ‘symbiotic’ were excluded. CHD, coronary heart disease; FOS, fructo- oligosaccharides; GOS, galacto- oligosaccharides; 
OFS, chicory root oligofructose; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus. aL. sporogenes is an invalid species name; this name has been used 
incorrectly by some to refer to Bacillus coagulans.
Table 1 (cont.) | Human trials of orally administered combinations of live microorganisms and a substrate reporting health outcomes
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Dietary History Questionnaire (DHQ), Automated Self- 
Administered 24- hour dietary assessment tool (ASA24) 
and nutrient analysis software (such as Nutrition Data 
System for Research).
Placebo or control. Design of a placebo or control is 
driven by the comparisons of interest. Often, a fully inert 
control is preferred. For formulations within pills or 
sachets, a low dose of highly digestible ingredients (such 
as maltodextrin or corn starch) or slowly fermentable 
fibre (such as microcrystalline cellulose) are acceptable 
placebos, which enables double blinding. For interven-
tions composed of a food or beverage, the control group 
must be carefully considered, including differences in 
flavour, texture and nutrient content. These factors will 
also determine whether the study can be considered as 
a single- blinded or double- blinded design.
Outcome. A synbiotic requires both a health outcome 
and a microbiota outcome in the same study. Primary and 
secondary health outcome(s) must be clearly specified. 
The microbiota outcome should be hypothesis- driven 
Box 2 | Actual and hypothetical examples to illustrate the synbiotic concept
The qualifier ‘established’ refers to a probiotic or prebiotic that meets the requirements of the globally accepted 
definitions from International Scientific Association for Probiotics and Prebiotics consensus12,13. Studies are done in 
the target	host.
Example 1
In a blinded four- arm study, 41 healthy volunteers received either Bifidobacterium animalis subsp. lactis bi-07 (109 CFu 
per day), 8 g per day xylo- oligosaccharides (XoS), the combination of both or an inert maltodextrin control for 21 days128. 
XoS enhanced bifidobacteria counts in faeces in both the synbiotic and prebiotic groups compared with the control and 
improved plasma lipid profiles and modulated markers of immune function in healthy adults. The lowest reported use 
of analgesics	was	observed	during	combination	supplementation	along	with	a	reduced	expression	of	CD19	on	B	cells	
(as markers	of	immune	function).	Thus,	the	combination	exerted	certain	benefits	that	were	not	afforded	by	the	probiotic	
or prebiotic alone. This study shows a prebiotic status for XoS used at 8 g per day. Previous evidence supports that 
Bifidobacterium animalis subsp. lactis bi-07 at 109 CFu per day met criteria for a probiotic112,129. Taken together, this tested 
product meets our definition of a complementary synbiotic. However, because an increase of Bifidobacterium was not 
observed in individuals fed the combination product, it does not meet our definition of a synergistic synbiotic.
Example 2
Krumbeck	et al.21 conducted a parallel multi- arm, double- blinded randomized control trial in people with obesity  
(17–19 per group) to assess the effects of a synbiotic containing 5 g of galacto- oligosaccharide (GoS) and 109 
Bifidobacterium adolescentis	IVS-1	on	gut	barrier	function.	The	test	strain	had	been	obtained	by	an	in vivo	selection	
strategy intended to select for strains that would be expected to provide synergistic outcomes. In addition to the 
synbiotic, GoS, B. adolescentis IvS-1 and placebo (lactose) controls were also included. After 3 weeks of consumption, 
genus- specific and strain- specific quantitative real- time PCr were performed to assess changes in absolute abundances 
of bifidobacteria. To assess intestinal permeability, non- metabolizable sugars were measured in urine following the 
consumption of a sugar mixture. Although the results showed that all three treatments (GoS only, B. adolescentis IvS-1 
only and the combination) markedly improved gut barrier function, there was no statistically significant difference 
among the three groups. The B. adolescentis IvS-1 group was significantly enriched but the addition of GoS as a synbiotic 
did not further increase strain abundance. likewise, all three treatments significantly increased the absolute abundance 
of faecal bifidobacteria compared to baseline, but there was no statistically significant difference among the three 
groups. Although the combination, probiotic and prebiotic arms all improved the markers of colonic permeability and  
all increased faecal bifidobacteria levels, the study did not support our definition of a synergistic synbiotic.
Example 3
In a hypothetical study, an established prebiotic substrate (for example, GoS or inulin) at the dose shown to be both 
selectively utilized and have a health benefit (primary outcome showing improved probably of response) is combined 
with an established probiotic at the dose shown to have a health benefit in the same target host. This combination 
product is tested and shown to confer a health benefit compared with the control (not necessarily the same benefit as 
previously tested for the probiotic and prebiotic). This product would meet our definition of a complementary synbiotic.
Example 4
In a hypothetical study, a substrate (not an established prebiotic) at 1 g per dose is combined with 106 CFu of a live 
microorganism (not an established probiotic). Preclinical testing suggests that the live microorganism selectively utilizes 
the substrate. A study tracking both health and microbiota end points in the target host comprises 106 CFu per dose of 
live microorganism alone, 1 g per dose of substrate, 106 CFu per dose of the live microorganism plus 1 g per dose of the 
substrate, and an inert control. microbiota analysis supports selective utilization by the combination. Concomitantly, a 
health or therapeutic end point is improved by the combination. The combined effect is better than the estimated effects 
of each component separately. This product would meet our definition of a synergistic synbiotic.
Example 5
A substrate (not an established prebiotic) plus a live microorganism (not an established probiotic) is tested against the 
control. It is found to confer a health benefit and increase levels of bifidobacteria in faeces. This result does not provide 
evidence for either a synergistic or complementary synbiotic. To fulfil criteria for a synergistic synbiotic, it must be 
demonstrated that the health benefit and selective utilization of the substrate exceed those observed for the control  
and for each individual component. As the materials comprising the mixture, at the dose used, were not established 
probiotics or prebiotics, it does not meet our definition of a complementary synbiotic.
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and provide insight into the microbiota- mediated 
mechanisms underlying the health outcome. Outcomes 
may include the abundance and viability of the admin-
istered live microorganism, changes in overall micro-
biota and/or microbiome composition, abundance of 
specific taxa and/or strains, microbial- derived metab-
olites, or others. Metabolomic analysis could also be 
performed using liquid chromatography–mass spec-
trometry, nuclear magnetic resonance or other suitable 
methods.
Statistics. A statistician’s involvement in the design phase 
of a study will provide confidence that the sample size 
is sufficient for the defined outcomes using intention- 
to- treat analysis. Mediation analyses might be useful to 
assess whether microbiota effects are contributing 
to the health benefit. Ancillary analyses, which could 
include population subgroups, responders versus non- 
responders or exploratory microbiota analyses should 
be pre- specified.
Finally, as with all trials, funding sources should be 
transparently reported, AEs must be carefully recorded 
and reported, and study design, execution and reporting 
should comply with CONSORT guidelines48 to minimize 
study bias.
Designing a synbiotic trial
There are multiple ways to design a synbiotic trial 
intended to examine health effects in the target host. 
Here, we provide some recommendations based on 
the criteria established herein to demonstrate com-
plementary or synergistic synbiotics. Pre- specified 
subgroup analyses should be considered based on the 
relevant clinical factors (such as sex and age), baseline 
gut microbiota factors, dietary factors (such as typical 
dietary fibre intake) or other relevant factors (such as 
responder analysis). The number of experimental groups 
or ‘study arms’ required to prove efficacy and support 
mechanistic understanding will depend on the existing 
level of evidence for the component live microorgan-
ism(s) and selectively utilized substrate(s) as well as the 
researchers’ intent to determine whether components 
of the test mixture are complementary or acting as 
synergistic synbiotics (TaBle 2).
When selecting the study design and determining 
the duration of the intervention and (if applicable) of the 
Table 2 | Evidence required for synbiotics using doses delivered in product
Composition Dosea Microbiological 
evidence from trial 
in target host
Study design Evidence of 
health benefit 
required from 
trial in target host
Complementary synbiotic
Prebiotic Sufficient to result in 
the selective utilization 
by resident microbiota 
and a health benefit 
in the absence of 




beyond that for the 
prebiotic component
Two- arm trial of 
complementary 





Probiotic Sufficient to result 
in a health benefit 
in the absence of 
the co- administered 
prebiotic
No effect on resident 
microbiota required
Two- arm trial of 
complementary 







utilized by the 
co- administered live 
microorganism
Sufficient to result in 
the selective utilization 
by the co- administered 
microorganism
Evidence that 
the substrate is 
selectively utilized by 
the co- administered 
live microorganism










synbiotic is better 
than the estimated 










the co- administered 
substrate and result in a 
health benefit
Evidence that 
the substrate is 
selectively utilized by 
the co- administered 
live microorganism










synbiotic is better 
than the estimated 
effects of each 
component 
separately
The unmodified term ‘synbiotic’ can be used on a commercial product label as long as the criteria for either a complementary or 
synergistic synbiotic are met. There is no restriction on the type of health target but it must be realistic and mechanistically driven. 
See TaBle 1 for a list of diseases and conditions targeted to date in human trials of putative synbiotics. Microbial, metabolic and 
health end points (or suitable biomarkers) must be tracked in the same study for a synergistic synbiotic, in the target host. It is not 
indicated here, but documentation of the safety of the final blended product for the intended use is required. aEffective doses 
delivered in a commercial product must be present through the end of shelf- life. bStudies documenting health benefits conferred 
by probiotic and prebiotic components are also required.
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wash- out period, general recommendations are difficult 
to make. Factors that will impact these decisions include 
the live microorganism dose and its ability to persist 
in situ as well as the characteristics of study subjects; 
for example, in elderly individuals or persons with slow 
intestinal transit time, a longer wash- out period could be 
required compared with a study conducted in younger 
individuals56. Parallel arm designs would be appropri-
ate for studies that aim to demonstrate improvements 
in metabolic health measures, such as of adiposity or 
glycaemic control, as these outcomes typically require 
longer- term interventions (that is, 12 weeks or more). 
Gut microbiota changes can be rapid (within days)60. 
Currently, changes in the gut microbiota and micro-
bial metabolites, such as short- chain fatty acids, are not 
accepted by regulatory bodies as measures of a health 
outcome61.
Responders and non- responders among study par-
ticipants in intervention studies with probiotics and 
prebiotics are commonly observed, which could justify 
including the probability of a positive response as a study 
end point. In the context of synbiotics, non- responders 
include individuals for whom little or no change in 
gut microbiota composition and/or clinical end point 
occurs compared with placebo. Various reasons for the 
non- responder phenotype include limited available 
niches for desired gut microorganisms (either native or 
introduced as probiotics)47, limited substrates to sup-
port microbial growth62, host immune system express-
ing intolerance for specific microorganisms63 or a lack 
of specific microorganisms in the host microbiota3. 
Although many scenarios of formulations for synbi-
otics can be conceived, we provide both actual and 
hypothetical examples to illustrate the concept (Box 2).
Trials for synergistic synbiotics. Studies on a synergis-
tic synbiotic that compare the synbiotic to the control 
can provide supportive evidence but do not constitute 
the primary evidence needed to confirm a synergistic 
synbiotic. Instead, a study including the combination, 
the substrate alone, the live microorganisms alone and a 
control should be conducted. Using an appropriate sta-
tistical model, the aim is to demonstrate that the com-
bined effect is better than the estimated effects of each 
component separately. Evidence of selective utilization 
of the substrate by the co- administered live microorgan-
ism must be obtained from the same trial demonstrating 
the health benefit.
Trials for complementary synbiotics. A two- arm paral-
lel or crossover study would be sufficient to test a com-
plementary synbiotic. The aim is to demonstrate that 
the combination is better than the placebo group with 
a relevant health end point. As a demonstrated prebiotic 
is used to formulate a complementary synbiotic, we do 
not require that selective utilization by the indigenous 
microbiota be reconfirmed in this clinical trial.
Measurement of selective utilization. Measurement of 
selective utilization by the microbiota might involve 
different approaches, including both in vitro model sys-
tems and in vivo studies in the target host. For example, 
selective utilization of a substrate could be demon-
strated experimentally using well- established in vitro 
gut models64 that include measurement of substrates and 
products during a prescribed time course. Ultimately, 
however, studies must be done in the target host to show 
that specific microorganisms or taxa had been enriched 
or their activity enhanced by a particular substrate. For 
synergistic synbiotics, methods that quantify the live 
microorganism should be used to show that the tar-
get strain has indeed been enriched21 and other suita-
ble methods can be used to show that its function has 
been enhanced. Microbiota features that are useful to 
measure can include characterization of the overall gut 
microbial community and microbiota diversity65, abun-
dance and/or activity of specific taxa66, microorganism–
microorganism or microorganism–host proximity67, 
the presence and/or abundance of specific microbial 
genes or gene clusters of interest, and/or metabolite 
concentrations68.
Safety measures for synbiotics
Prebiotics and probiotics tested to date have a strong 
safety record69–74, and synbiotics formulated with them 
might also be presumed safe for the same intended uses. 
However, novel formulations must be suitably assessed 
for safety. Unfortunately, historically, many probiotic 
and prebiotic intervention trials have not adequately 
reported the types and frequency of AEs or serious AEs, 
perhaps owing to expectations that, as food ingredients, 
these products were inherently safe or that AEs could be 
due to failure to comply with norms for reporting harms 
in RCTs. Nonetheless, clear guidance for reporting AEs 
and serious AEs is provided by CONSORT75 and these 
standards should be followed. Describing such events as 
“unrelated to the study product”, without justification for 
this statement, is unacceptable.
A systematic review of 384 interventions involv-
ing prebiotics, probiotics and synbiotics found that no 
safety- related data were reported in 37% of the RCTs 
and 89 studies only used generic statements to describe 
AEs76. Up to 98% of studies did not provide a definition 
of AEs or serious AEs, the number of participant with-
drawals due to AEs, or the number of AEs and serious 
AEs per study group. Taken together, these results are 
evidence that some studies inadequately collect or report 
data on AEs. van den Nieuwboer and colleagues72,77–79 
reviewed the AEs reported in studies with probiotic and 
synbiotic interventions and classified them according to 
the Common Terminology Criteria for Adverse Events 
system80; they found that the incidence of AEs in each 
category was either no different from or often lower in 
the control groups than in the treatment group.
Thorough safety assessment of a synergistic synbiotic 
requires consideration that the added microorganism 
will express enhanced functionality in the presence of 
a targeted substrate such as improved growth or altered 
metabolic or physiological activity in vivo. This aspect 
suggests that safety assessments conducted on the live 
microorganism in isolation might not be sufficient to 
enable a conclusion about its safety when paired with 
a substrate that alters physiology or might in effect 
alter the dose delivered in vivo. Implications of such an 
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interaction should be considered when assessing the 
safety of synergistic synbiotics.
Implications of this consensus
The panel recognizes the importance of developing a 
scientifically valid definition of the term synbiotic. The 
intention is to provide clarity for a diverse range of stake-
holders, including consumers, regulators, health- care 
providers, researchers, industry and scientific organ-
izations communicating about synbiotics. TaBle 3 is 
designed to clearly lay out the criteria for synbiotics 
in comparison to probiotics and prebiotics. Within 
the commercial supply chain, many different industry 
sectors, including ingredient suppliers, end- product 
manufacturers and retailers are very interested in 
how synbiotics are defined. As synbiotic products are 
being used more frequently in clinical trials, it is incum-
bent upon scientists to clarify the appropriate use of 
this term as has been done for the terms ‘probiotic’12  
and ‘prebiotic’13.
Although the term ‘synbiotic’ might not be as well 
recognized as probiotics and prebiotics, it is nonetheless 
found on product labels, in popular press articles and in 
the scientific literature. The first mention of a synbiotic 
was in 1995 yet, according to PubMed searches, in 2019, 
269 papers were published using the term. Consumer 
exposure is expected to increase. Thus, it is hoped that 
the definition herein is clear and widely accepted and 
will counter misuse of the term, including by scientists8. 
TaBle 3 provides the minimum criteria for the correct 
use of terms associated with synbiotics.
The importance of context. The panel urges stakehold-
ers to carefully consider context for communications 
to consumers on the health benefits of synbiotics. The 
overall impression of any communication should lead 
consumers to understand the claim in a manner that is 
consistent with the evidence; any misleading use of the 
term constitutes misuse. Communication of the tested 
health benefit must accurately reflect what was reported 
in the clinical trial; results should not be extrapolated to 
health conditions, populations or synbiotics that have 
not been studied.
Regulators. Regulatory authorities are primarily focused 
on two issues: product safety and product labelling. 
These encompass both truthfulness and compliance 
with regulatory statutes. Even if the term synbiotic is not 
included in governmental guidelines or regulations, the 
use of our proposed scientific definition of the term will 
aid regulatory oversight of products labelled as ‘synbiotic’.
Regulatory statutes will differ with regard to geo-
graphical regions, regulatory categories, types of allow-
able claims and premarket approval. Furthermore, 
different standards exist for manufacturing, efficacy 
and safety depending on geographical region and prod-
uct category. The term synbiotic does not stipulate 
a regulatory category, so (simply stated), regulatory 
requirements for a synbiotic would need to meet those 
that apply to the category (for example, drug, food or 
supplement) of the marketed product.
Regulatory complications can result in regions that 
impose probiotic- specific regulations. For example, 
Canada81,82, Italy83, Argentina84, Chile85, Colombia86 and 
Brazil87 have requirements specific to probiotic foods or 
supplements. Furthermore, there is a proposal88 under 
consideration by Codex Alimentarius that could result 
in probiotic- specific global standards89. The Codex 
Alimentarius is a collection of standards, guidelines 
and codes of practice adopted under the auspices of 
the Food and Agricultural Organization of the United 
Nations and World Health Organization to protect con-
sumer health and promote fair practices in food trade. 
Codex Alimentarius standards could affect probiotic 
products traded globally. Could product manufacturers 
potentially avoid these regulations by labelling a product 
Table 3 | Minimum criteria to appropriately use the terms ‘probiotic’, ‘prebiotic’ and ‘synbiotic’
























Selective utilization of 
substrate

















Probiotic ☑ ☑ ☑ ☑ ☑ NA NA NA ☑ NA ☑





☑ ☑ ☑ ☑ ☑ ☑ ☑ –a ☑ NR ☑
Synergistic 
synbiotic
☑ ☑ ☑ ☑ ☑ ☑ –a ☑ ☑ ☑ ☑
Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. A prebiotic is a substrate that is selectively 
utilized by host microorganisms conferring a health benefit. Synbiotics are a mixture comprising live microorganisms and substrate(s) selectively utilized by host 
microorganisms that confers a health benefit on the host. A complementary synbiotic is a mixture of a probiotic plus a prebiotic. A synergistic synbiotic is a 
synbiotic in which the substrate is designed to be selectively utilized by the co- administered microorganisms. A synbiotic must meet the evidence required for 
either complementary or synergistic synbiotics. All substances should be made available to the scientific community for validation of research findings. aThe intent 
of a synergistic synbiotic is for the substrate to support the growth and/or activity of the co- administered live microorganisms but selective utilization by the 
resident microbiota is not a disqualifier. The prebiotic component of a complementary synbiotic must be selectively utilized by the resident microbiota, but if it  
is also utilized by the co- administered probiotic, it is not a disqualifier. NA, not applicable; NR, not required.
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as a synbiotic? Without the use of the term probiotic or 
prebiotic, relevant specific regulations would not be trig-
gered. Perhaps this approach would not provide a mar-
keting advantage, as consumer recognition and demand 
for synbiotic products is currently not as advanced as for 
probiotics and prebiotics. However, regions supporting 
probiotic- specific (or prebiotic- specific) regulations will 
need to address how the concept of synbiotics fits into 
those regulations. Our stipulation is that manufactur-
ers of complementary synbiotics should meet current 
probiotic or prebiotic regulations.
One regulatory consequence of probiotic and pre-
biotic definitions is that the European Union has deter-
mined that labelling a food product as such amounts 
to an implied health claim90. As health claims in the 
European Union must be approved, the use of ‘probiotic’ 
or ‘prebiotic’ on a food label is subject to a health claim 
approval process. Despite controversy surrounding this 
situation, we can expect that the European Union might 
adopt a similar position for the use of the term ‘synbiotic’ 
because it also requires evidence of a health benefit.
Scientists. Synbiotics present challenges for research-
ers, including deciphering mechanisms underlying 
the health benefit and proving that the microbiota are 
modulated via complementary or synergistic means. 
Unless appropriate experimental methods of verification 
are used, the product under assessment should not be 
referred to as ‘synbiotic’.
As for probiotics, prebiotics and synbiotics, it might 
be possible a priori to stratify study participants to 
enhance either the magnitude of the response or the 
number of responders to a given synbiotic treatment. 
The baseline composition of gut microbiota of study par-
ticipants could be one useful stratification factor91,92. This 
stratification might improve mechanistic understanding 
of observed effects and could be useful for character-
izing responders and non- responders. Ultimately, this 
approach could enable better translation of clinical trial 
outcomes to those who are likely to benefit.
Scientists involved in the publication process (authors, 
editors, reviewers) should use the term synbiotic correctly 
and reject erroneous or unsupported use of the term. Even 
if a given treatment fails to demonstrate an effect (that is, 
acceptance of the null hypothesis) in a well- conducted 
study, such results still warrant publication93.
Industry. The business community plays a vital part 
in translating the outcomes of fundamental and clini-
cal research into commercial products that can benefit 
consumers. To the extent that industry funds research, 
it is essential that studies adhere to well- established 
guidelines to manage conflicts of interest and minimize 
bias94,95. Further, industry bears the duty of responsible 
manufacture, quality control and marketing of synbiotic 
products. It is incumbent on industry to follow good 
manufacturing practices, engage in truthful labelling 
and product promotion as well as adhere to appropriate 
use of the term ‘synbiotics’.
Media. The media (TV, radio, newspapers, magazines, 
websites and social media) have an increasingly central 
role in communicating science. These efforts require 
commitment and skill to craft clear, simple messages 
that are true to the science. Too often, scientists or their 
institutions do not effectively translate complex research 
findings so that they can be understood by the lay pub-
lic. At times, overextended or inflated representations of 
research findings can be communicated through official 
academic or journal press releases. Communicators are 
therefore encouraged to distinguish between association 
studies and those presenting causal evidence, to describe 
single studies in the context of the totality of evidence, to 
avoid overgeneralizing results (for example, from model 
organisms such as mice) and to note study limitations. 
This requirement is true for null studies as well as those 
suggesting benefits from the interventions being tested. 
In this context, the media should adopt the scientific 
definition of synbiotics herein.
Conclusions
This Consensus Statement provides a new definition 
for a ‘synbiotic’ based on review by a panel of experts. 
To summarize (Box 1), a synbiotic is a mixture comprising 
live microorganisms and substrate(s) selectively utilized 
by host microorganisms that confers a health benefit on 
the host. Two categories of synbiotics are recognized. 
A complementary synbiotic is composed of a probiotic 
and a prebiotic that together confer one or more health 
benefits but do not require co- dependent function; the 
components must be used at doses that have been shown 
to be effective for the components alone. A synergistic 
synbiotic contains a substrate that is selectively utilized 
by the co- administered live microorganism(s). Synbiotic 
products are not confined to human applications but 
could also include companion animals and livestock. 
They might also be directed to specific subpopulations 
(age, sex, health status) of the target species. The defini-
tion can also be applied to intestinal or extra- intestinal 
microbial ecosystems. The hope is that, going forward, 
this updated definition will be utilized and that it will 
aid in advancing synbiotic research, improve stakeholder 
understanding and enable better communication to 
consumers.
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